Establish strategies of national vaccine development throughout the full cycle and support its commercialization
Operate and manage the Infrastructure of Korea Vaccine Research Center(K-VRC)
Establish/operate the vaccine development cooperation system domestically and internationally
Research Areas
Strengthen governance to support the full-cycle of vaccine R&D
Enact/amend related laws and administrative rules, establish/adjust mid- to long-term plans for establishing a support system for vaccine R&D
Operate a cooperation system between related ministries to promote integrated support measures for developing the COVID-19 vaccines
Internal and external collaboration for vaccine development
Expand and strengthen partnerships with multiple agencies and ministerial organizations, private organizations, international organizations, and overseas agencies for global cooperation and joint countermeasures
Establish national infrastructure for vaccine R&D and expand non-clinical support to it
Promote efficiency of supporting the evaluation of its effectiveness (Immunogenicity Assay, In vivo) by developing detailed operation management guidelines and standard operating procedures and establishing a portal system
Support equipment and experiments for analyzing the effectiveness of candidate vaccines developed in the private sector.
Continue non-clinical support on the private sector through verifying biosafety level 3 laboratory and expanding its operation
Strategic development of public vaccines and supporting it
Strengthen and support infectious disease research, such as in-house development (candidate material development) and technology securement of vaccines for unsolved infectious disease
Expand the project of non-clinical research on public vaccine development (Establishment of standard animal models and non-clinical standard test methods)
Purpose
Strengthen the national safety net to manage infectious diseases by developing vaccines against them and securing basic technologies
Research Areas
Secure a platform for rapid vaccine development to manage emerging infectious diseases.
Secure mRNA-based vaccine technology through domestic and international joint research. Then, establish a platform technology for rapid vaccine development.
Develop various state-of-the-art vaccine platform technologies such as viral vector and subunit
Strengthen the vaccine development capabilities for major infectious diseases and countermeasures to them in the future
R&D of vaccine to manage unresolved infectious diseases, such as next-generation tuberculosis and mumps
R&D of vaccine to manage Emerging infectious diseases such as COVID-19, Zika, SFTS
Promote the development of full-cycle public vaccines against viruses, such as third-generation smallpox and adenovirus type 55, to secure national security
Secure vaccine technology of enhancing immunity
Develop and apply vaccine delivery technologies, such as administration methods and vaccine formulations applicable to various vaccine platforms
Search Immune boosters through public-private cooperation and technology introduction, and promote research on the evaluation of its efficacy
Promote translational research on developing vaccines
Support non-clinical research on the developed vaccine for diseases, such as COVID-19
Strengthen the domestic and international R&D cooperative system for the Vaccine lifecycle
Strengthen the existing infrastructure and establish an International Joint Research Network to promote the commercialization of public vaccines
Purpose
Collect, manage, and utilize pathogen resources
Collect, analyze, and evaluate pathogen resources
R&D using pathogen resources
Establish and operate pathogen resource-related infrastructure
Establish and operate the distribution system of information on Pathogen Resources
Research Areas
Secure useful pathogen resources and enhance stable conservation management capabilities
Expand qualitative, quantitative, and strategic collection of pathogen resources
Establish the system of conservation and management that secures the usefulness and stability of pathogen resources
Enhance the management base of pathogen resources and overhaul its system
Enhance the value of pathogen resources and promote their distribution and utilization
Add values of Pathogen Resources
Strengthen the foundation to promote the use of useful pathogen resource
Establish the cooperative network of domestic and international pathogen resources
Establish the cooperative network of international pathogen resources
Strengthen domestic connection and cooperation on pathogen resources through communication and participation
Purpose
Securing vaccine sovereignty by upgrading the international-level vaccine clinical research system
Research Areas
Vaccine clinical test policy planning
Establish clinical test strategies on Emerging infectious diseases and undeveloped vaccines
Operate an expert council for clinical test support and collaboration on internal and external clinical research
Design domestic vaccine clinical tests and provide advice
Establish vaccine’s clinical test cluster to vitalize research on vaccine clinical tests
Establish mid- to long-term plans for clinical research and its road-maps to develop vaccines in Korea.
Vitalize clinical test translational research to commercialize vaccines
Support private sectors to evaluate the efficacy of vaccine clinical tests
Support the commercialization of vaccine candidates
Support clinical test and clinical specimen analysis
Provide facilities, equipment, and technologies to vitalize clinical tests
Develop the evaluation index of vaccine's clinical test and its analysis program
Develop and standardize immunogenicity evaluation methods and standard materials
Establish and supply an infrastructure system of analyzing clinical specimens while meeting international standards
Investigate and research vaccination-related immunity
Perform a study on immunity to establish a management plan for infectious diseases, national vaccination policy, and quarantine measures
Investigate antibodies to novel infectious diseases, such as COVID-19, and evaluate immunogenicity after vaccination
